187 related articles for article (PubMed ID: 36269794)
21. High baseline total lesion glycolysis predicts early progression of disease within 24 months in patients with high-tumor-burden follicular lymphoma.
Kuroki W; Kitadate A; Ishiyama K; Kameoka Y; Takahashi N
Int J Hematol; 2022 Nov; 116(5):712-722. PubMed ID: 35857194
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.
Kwon M; Ku BM; Olsen S; Park S; Lefterova M; Odegaard J; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Cancer Med; 2022 Aug; 11(15):2944-2956. PubMed ID: 35437925
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK).
Moccia AA; Schär S; Hayoz S; Pirosa MC; Taverna C; Novak U; Kimby E; Ghielmini M; Zucca E
Br J Haematol; 2021 Mar; 192(6):1031-1034. PubMed ID: 32805081
[TBL] [Abstract][Full Text] [Related]
24. Early Progressing Follicular Lymphoma.
Wallace D; Casulo C
Curr Oncol Rep; 2021 Nov; 23(12):149. PubMed ID: 34797453
[TBL] [Abstract][Full Text] [Related]
25. Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma.
Delfau-Larue MH; van der Gucht A; Dupuis J; Jais JP; Nel I; Beldi-Ferchiou A; Hamdane S; Benmaad I; Laboure G; Verret B; Haioun C; Copie-Bergman C; Berriolo-Riedinger A; Robert P; Casasnovas RO; Itti E
Blood Adv; 2018 Apr; 2(7):807-816. PubMed ID: 29636326
[TBL] [Abstract][Full Text] [Related]
26. Expression of glucose transporter-1 in follicular lymphoma affected tumor-infiltrating immunocytes and was related to progression of disease within 24 months.
Deng Y; Ma J; Zhao S; Yang M; Sun Y; Zhang Q
Transl Oncol; 2023 Feb; 28():101614. PubMed ID: 36584488
[TBL] [Abstract][Full Text] [Related]
27. Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR-TKI treatment in advanced non-small cell lung cancer.
Zheng J; Wang Y; Hu C; Zhu M; Ii J; Lin C; Lu C; Dou Y; Zhao C; Zhang Y; Wu D; Li L; Tang H; He T; Pan C; Han R; He Y
Thorac Cancer; 2022 Nov; 13(22):3162-3173. PubMed ID: 36193794
[TBL] [Abstract][Full Text] [Related]
28. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
Russler-Germain DA; Krysiak K; Ramirez C; Mosior M; Watkins MP; Gomez F; Skidmore ZL; Trani L; Gao F; Geyer S; Cashen AF; Mehta-Shah N; Kahl BS; Bartlett NL; Alderuccio JP; Lossos IS; Ondrejka SL; Hsi ED; Martin P; Leonard JP; Griffith M; Griffith OL; Fehniger TA
Blood Adv; 2023 Sep; 7(18):5524-5539. PubMed ID: 37493986
[TBL] [Abstract][Full Text] [Related]
29. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
[TBL] [Abstract][Full Text] [Related]
30. Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma.
Yoon SE; Shin SH; Nam DK; Cho J; Kim WS; Kim SJ
Cancer Res Treat; 2024 Jan; ():. PubMed ID: 38228081
[TBL] [Abstract][Full Text] [Related]
31. Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study.
Lee JS; Han Y; Yun WG; Kwon W; Kim H; Jeong H; Seo MS; Park Y; Cho SI; Kim H; Kim JY; Seong MW; Jang JY; Park SS
Clin Chem; 2022 Dec; 68(12):1509-1518. PubMed ID: 36177751
[TBL] [Abstract][Full Text] [Related]
32. Individualized Mini-Panel Sequencing of ctDNA Allows Tumor Monitoring in Complex Karyotype Sarcomas.
Braig D; Runkel A; Eisenhardt AE; Schmid A; Zeller J; Pauli T; Lausch U; Wehrle J; Bronsert P; Jung M; Kiefer J; Boerries M; Eisenhardt SU
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142126
[TBL] [Abstract][Full Text] [Related]
33. Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer.
Carrasco R; Ingelmo-Torres M; Gómez A; Trullas R; Roldán FL; Ajami T; Moreno D; Rodríguez-Carunchio L; Alcaraz A; Izquierdo L; Mengual L
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233035
[TBL] [Abstract][Full Text] [Related]
34. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
[TBL] [Abstract][Full Text] [Related]
35. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A
Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494
[TBL] [Abstract][Full Text] [Related]
36. Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer.
Wei T; Zhang Q; Li X; Su W; Li G; Ma T; Gao S; Lou J; Que R; Zheng L; Bai X; Liang T
Mol Cancer Ther; 2019 Jan; 18(1):196-203. PubMed ID: 30301865
[TBL] [Abstract][Full Text] [Related]
37. [Clinical Features of Diffuse Large B-Cell Lymphoma Transformed from Follicular Lymphoma].
Zhang XL; Yu WJ; Zhu YN; Yang CM; Xiao F; Mai WY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1772-1778. PubMed ID: 36476902
[TBL] [Abstract][Full Text] [Related]
38. Liquid biopsy: current technology and clinical applications.
Nikanjam M; Kato S; Kurzrock R
J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847
[TBL] [Abstract][Full Text] [Related]
39. Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up.
Boons G; Vandamme T; Mariën L; Lybaert W; Roeyen G; Rondou T; Papadimitriou K; Janssens K; Op de Beeck B; Simoens M; Demey W; Dero I; Van Camp G; Peeters M; Op de Beeck K
Clin Cancer Res; 2022 Jan; 28(2):338-349. PubMed ID: 34759042
[TBL] [Abstract][Full Text] [Related]
40. Liquid biopsy in extranodal NK/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring.
Qi F; Cao Z; Chen B; Chai Y; Lin J; Ye J; Wei Y; Liu H; Han-Zhang H; Mao X; Feng X; Dong M
Blood Adv; 2021 Jun; 5(11):2505-2514. PubMed ID: 34047776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
